• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Trial of low doses of aspirin as prophylaxis in sickle cell disease.

作者信息

Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E

出版信息

J Pediatr. 1983 May;102(5):781-4. doi: 10.1016/s0022-3476(83)80258-3.

DOI:10.1016/s0022-3476(83)80258-3
PMID:6842340
Abstract

The effects of low doses of aspirin on the frequency and severity of painful vaso-occlusive crises were evaluated in children with sickle hemoglobinopathies. Aspirin was compared with placebo in 49 patients in a double-blind crossover study. Careful monitoring of patients revealed an average of 1.1 painful crises per patient year. During the 21 months of study, 70% of patients had a maximum of two painful crises, and 25% experienced four or more. The frequency and severity of crises were not affected by aspirin therapy. In view of aspirin's demonstrated effect on platelet function, we suggest that platelets do not contribute to the initiation or progression of the vaso-occlusive process.

摘要

相似文献

1
Trial of low doses of aspirin as prophylaxis in sickle cell disease.
J Pediatr. 1983 May;102(5):781-4. doi: 10.1016/s0022-3476(83)80258-3.
2
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.DOVE(确定血小板抑制对血管闭塞事件的影响)试验设计:一项全球性3期双盲、随机、安慰剂对照、多中心研究,采用剂量滴定策略评估普拉格雷在镰状细胞贫血儿科患者中的疗效和安全性。
Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24.
3
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.一项评估普拉格雷治疗镰状细胞血管阻塞事件的多国临床试验。
N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.
4
Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.在一项关于普拉格雷治疗镰状细胞贫血患儿的双盲研究中,使用即时血小板反应性检测进行实时剂量调整。
Thromb Haemost. 2017 Feb 28;117(3):580-588. doi: 10.1160/TH16-09-0731. Epub 2016 Dec 8.
5
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3).替卡格雷洛与安慰剂治疗小儿镰状细胞病血管闭塞性危象的比较:一项随机、双盲、平行分组、多中心 3 期研究(HESTIA3)的原理和设计。
Contemp Clin Trials. 2019 Oct;85:105835. doi: 10.1016/j.cct.2019.105835. Epub 2019 Aug 22.
6
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.羟基脲与镰状细胞贫血。一种骨髓抑制性“转换”药物的临床应用。羟基脲治疗镰状细胞贫血多中心研究。
Medicine (Baltimore). 1996 Nov;75(6):300-26. doi: 10.1097/00005792-199611000-00002.
7
Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease.吡拉西坦对预防镰状细胞病儿童和青少年疼痛性危象无效。
Acta Haematol. 2005;113(4):228-33. doi: 10.1159/000084675.
8
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.替卡格雷洛对比安慰剂用于降低小儿镰状细胞病的血管阻塞性危象:HESTIA3 研究。
Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095.
9
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.克立硃单抗用于预防镰状细胞病的疼痛危象
N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.
10
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.羟基脲对镰状细胞贫血疼痛性危象发作频率的影响。镰状细胞贫血羟基脲多中心研究的研究者们。
N Engl J Med. 1995 May 18;332(20):1317-22. doi: 10.1056/NEJM199505183322001.

引用本文的文献

1
Prevalence of Antiplatelet and Anticoagulation Therapy in Children with Sickle Cell Anemia and Stroke.镰状细胞贫血和中风患儿中抗血小板和抗凝治疗的患病率。
Pediatr Stroke. 2025;11:111-140.
2
Megakaryocytes transfer mitochondria to bone marrow mesenchymal stromal cells to lower platelet activation.巨核细胞将线粒体转移至骨髓间充质基质细胞以降低血小板活化。
J Clin Invest. 2025 Feb 27;135(8). doi: 10.1172/JCI189801. eCollection 2025 Apr 15.
3
The Role of Antiplatelet in the Management of Sickle Cell Disease Patients.抗血小板药物在镰状细胞病患者管理中的作用
Cureus. 2023 Jul 18;15(7):e42058. doi: 10.7759/cureus.42058. eCollection 2023 Jul.
4
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.新冠病毒感染与镰状细胞病中的血栓炎症:同一枚硬币的两面
Biomedicines. 2023 Jan 25;11(2):338. doi: 10.3390/biomedicines11020338.
5
Sickle cell vaso-occlusion: The dialectic between red cells and white cells.镰状细胞血管阻塞:红细胞与白细胞的辩证关系。
Exp Biol Med (Maywood). 2021 Jun;246(12):1458-1472. doi: 10.1177/15353702211005392. Epub 2021 Apr 1.
6
Culturable bacteria associated with Anopheles darlingi and their paratransgenesis potential.与致倦库蚊相关的可培养细菌及其共生转化潜力。
Malar J. 2021 Jan 13;20(1):40. doi: 10.1186/s12936-020-03574-1.
7
Drug Therapies for the Management of Sickle Cell Disease.用于镰状细胞病管理的药物疗法
F1000Res. 2020 Jun 11;9. doi: 10.12688/f1000research.22433.1. eCollection 2020.
8
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.镰状细胞病治疗中不断演变的药物治疗格局。
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020010. doi: 10.4084/MJHID.2020.010. eCollection 2020.
9
Role of the coagulation system in the pathogenesis of sickle cell disease.凝血系统在镰状细胞病发病机制中的作用。
Blood Adv. 2019 Oct 22;3(20):3170-3180. doi: 10.1182/bloodadvances.2019000193.
10
Advances in new drug therapies for the management of sickle cell disease.镰状细胞病治疗新药疗法的进展。
Expert Opin Orphan Drugs. 2018;6(5):329-343. doi: 10.1080/21678707.2018.1471983. Epub 2018 May 14.